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An In-vitro Skin Wound Infection Model and Bioevaluation of Antimicrobial 
Wound Dressings
Introduction: Chronic wounds and associated delayed healing has become a great challenge in wound care and management. In this respect,
development of human-based three-dimensional in-vitro systems with bacterial infection and biofilm formation is highly demanding to study
biological properties of novel antimicrobial polymeric biomaterials (AMBs) as well as to understand underlying pathophysiology of chronic wounds
for successful healing. An in-vitro wound infection model will serve as an advanced and complex system to perform more reliable preclinical
studies for the bioevaluation of cytotoxicity, antimicrobial as well as wound healing properties of AMBs in a biomimetic system of the in vivo state
of chronic wounds.
Methods: The 3D skin equivalent was obtained having both a dermal and an epidermal compartment, by embedding human primary fibroblasts
in rat tail tendon collagen type I hydrogel (mimicking skin extracellular matrix) and then seeding human primary keratinocytes on it to generate
the epidermal layer. The model was characterized for morphological characteristics and dermal/epidermal markers through histological and
immunohistochemical analysis. To generate wound infection model, this system was inoculated with clinically challenging bacteria e.g.
Staphylococcus aureus (ATCC 29213) into full thickness wounds. Commercially available wound dressings like "Atrauman® Ag" were evaluated for
antibacterial as well as cytotoxic properties in this 3D system. To assess the viability of the system quantitatively, cytotoxicity assays e.g. CytoTox-
ONE (Promega) were used.
Fig 1: Development of In-vitro Skin Model
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Fig 1: Hematoxylin/Eosin (H & E) stained histological images of in vitro 3D
human skin model. The results show the two structurally distinct layers of skin:
the outer epidermis layer and the underlying thicker dermis layer that consists
of connective tissue. The epidermal part shows well differentiated layers of
keratinocytes namely stratum corneum, granulosum, spinosum and basale.
Furthermore, the contact between dermal and epidermal surface is not straight
rather it is undulating in a way that it intertwines with dermal layer; mimicking
the in vivo situation.
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Fig 2: In-vitro human skin model recapitulates the epithelial differentiation found in healthy human skin; and
thus can be termed as skin equivalent. The epidermis is stratified squamous epithelium that makes the
protective covering of the skin. The innermost cells of the epidermis have the capacity for DNA synthesis and
mitosis. Under a trigger of terminal differentiation, the basal cell begins its journey to the surface. In transit, it
undergoes a series of morphological and biochemical changes associated with the expression of differential
markers at different stages of its differentiation cycle.
The images show immunolabelling for specific epidermal differentiation markers of in-vitro 3D human skin: (a)
Keratin 14 (K14) red, (b) Keratin 10 (K10) green, (c) Ki67 (a cellular proliferation marker protein) green, (d)
Laminin 5 (Lam 5) green. Cell nuclei are shown in blue by using DAPI staining.
In particular, basal and suprabasal layers show Keratin 14 and Keratin 10 respectively, while presence of Ki67
cells (arrows) shows the proliferative state of basal epidermal cells. Laminin 5 is used as a marker of dermo-
epidermal junction (DEJ) and appeared as a thin line.
Fig 4: Cell viability of the 3D skin infection model is characterized by measuring the amount of dead cells based
on LDH measurements of: 1) In-vitro Skin Wound Model after wounding called “Wound Control” 2) S. aureus
colonization of Wound Control served as “Wound Infection Model” 3) Treatment of Wound Infection Control
with the antimicrobial wound dressing Atrauman® Ag named as “Treated (Atrauman® Ag) Group”. The results
indicate an affected cell viability after wound infection that decreases over time. This effect can be a result of
cytotoxic effect of bacteria on cells and/or utilization of the nutrients by bacteria to form biofilm.
Surprisingly, the cytotoxicity values are higher in treated group than in Wound Infection Control. Inability of
Atrauman® Ag to eradicate bacteria can be a reason for this increasing detrimental effect on cells in treated
group. However, evaluation of cytotoxic effects of Atrauman® Ag on cells alone without bacteria (i.e. Skin
Wound Model) has to be investigated to answer this question.
Fig 5: The graph shows the treatment
of S. aureus colonized skin infection
model. Skin equivalents were infected
with S. aureus and treated with
Atrauman® Ag versus PBS. Twenty-
four hours after treatment the
number of bacteria was determined.
The results show that Atrauman® Ag
was able to reduce bacterial burden
to some extent but not to eradicate
the bacteria completely.
Fig 3: a) Microscopic analysis of bacterial replication and
biofilm formation on in-vitro skin model. Skin equivalents were
exposed to S. aureus for 24 h. Thereafter the skin sections
were stained with H & E staining and analyzed by light
microscopy. The results reveal that inoculated S. aureus is able
to adhere to the dermal surface, colonize, and replicate to
make large structures of biofilm. Also, the bacteria did not
persist on the surface, rather invaded through the whole
dermal depth. Big arrows indicate bacteria within a biofilm
matrix inside dermis. Small arrows indicate the bacteria
surrounding keratinocytes in epidermis. How do these bacteria
affect skin cells, needs further investigation. b) The graph
shows replication of S. aureus on in-vitro skin model over 24 h.
This graph shows the bacterial growth rate on this biotic
surface, indicating that bacteria are able to increase their
population on an in-vitro skin to 99.99% in 24 h. The ability of
S. aureus to form a biofilm on human skin plays an important
role in its persistence on the skin infection.
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Fig 4: Cytotoxicity Measurement of Materials on In-vitro 3D Skin Infection Model Fig 5: Treatment of S. aureus Colonized Skin Infection 
Model
Fig 2: Characterization of In-vitro Skin Model
Fig 3: Development  & Characterization of In-vitro Skin 
Infection Model
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Summary: With an increasing need for novel strategies to
combat persistent infectious wounds, there is an urgent need
to understand basic aspects of the host-pathogen relationship;
as well as a more in-vivo like screening tool to study the
efficacy of antimicrobials. In this study, we intend to
successfully create a full thickness infected skin equivalent, to
serve as a risk assessment platform, representing healthy and
infected skin.
